Substance / Medication

Alfuzosin hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Benign prostatic hyperplasia

Hyperplasia of prostate

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Prostate specific Ag

LOINC 10508-0

secondary

Research Evidence

Published studies and systematic reviews

Sort:

Design and optimization of gastric floating sustained-release mini-tablets of alfuzosin hydrochloride based on a factorial design: in vitro/in vivo evaluation.

Gong Ling, Yu Miao, Sun Yanyan et al. · Drug Dev Ind Pharm · 2018

PMID: 30058391Observational

In vitro controlled release of alfuzosin hydrochloride using HPMC-based matrix tablets and its comparison with marketed product.

Nair Anroop, Gupta Rachna, Vasanti Sutrave · Pharm Dev Technol · 2007

PMID: 18161635Observational

Validated HPLC and HPTLC stability-indicating methods for determination of alfuzosin hydrochloride in bulk powder and pharmaceutical formulations.

Salah Fayed Ahmed, Abdel-Aaty Shehata Mostafa, Yehia Hassan Nagiba et al. · J Sep Sci · 2006

PMID: 17305232Observational

Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.

Lee Mary · Am J Health Syst Pharm · 2003

PMID: 12892027Observational

Utilization of absorbance subtraction and ratio difference green spectrophotometric methods for the quantification of alfuzosin hydrochloride and tadalafil in their binary mixture.

Alqahtani Ali, Alqahtani Taha, Ramzy Sherif · BMC Chem · 2024

PMID: 38725069OtherFull text (PMC)

Micellar-enhanced and green-assessed first-derivative synchronous spectrofluorimetric approach for concurrent determination of alfuzosin hydrochloride and solifenacin succinate in different matrices: Docking simulation.

Sayed Rania A, Mohamed Ahmed R, Shalaby Abdalla et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2023

PMID: 36758367Other

Green micellar liquid chromatographic analysis of alfuzosin hydrochloride and sildenafil citrate in a binary mixture compared to classical RPLC with stability indicating studies.

Ayad Magda Mohamed, Hosny Mervat Mohamed, Metias Youstina Mekhail · Drug Dev Ind Pharm · 2022

PMID: 35754330Other

Utilization of a micellar matrix for simultaneous spectrofluorimetric estimation of alfuzosin hydrochloride and vardenafil hydrochloride.

Elama Heba Samir, Shalan Shereen M, El-Shabrawy Yasser et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2022

PMID: 34619505Other

Development of green differential pulse voltammetric strategy for the determination of alfuzosin hydrochloride at pencil graphite and modified carbon paste electrodes.

Metias Youstina Mekhail, Hussien Emad Mohamed, Hosny Mervat Mohamed et al. · Acta Chim Slov · 2022

PMID: 36196814Other

Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development,characterization and gastroretentive monitoring in healthy volunteers via MRI.

Abd El-Aziz Marwa Farrag, Ismail Soha, Tadros Mina Ibrahim et al. · Pharm Dev Technol · 2020

PMID: 31967910Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

Urology

Health Goals

Goals connected through associated conditions

Support Prostate Health

Quick Facts

Type: Substance / Medication
Fully Specified Name: Alfuzosin hydrochloride (substance)
SNOMED CT: 395725004
UMLS CUI: C0102130

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.